P eak oxygen uptake (peak VO 2 ), the standard for assessing cardiovascular fitness, is a strong prognostic indicator in chronic heart failure (HF) and is a criterion variable for consideration of cardiac transplantation in such patients. 1,2 Peak VO 2 , when reported relative to body mass, is responsive to a number of interventions, including drug and device therapies, exercise training, and changes in body weight. [3] [4] [5] [6] Although the prognostic ability of a single measurement of peak VO 2 is well established, the relation between a change in peak VO 2 and clinical outcomes is not well defined. Prior studies have involved relatively small samples, and the findings are not consistent. 7-11 Studying the change in peak VO 2 and its relation with clinical outcomes would be beneficial for assessing the course of HF and to evaluate the result of a therapeutic intervention such as exercise training, medication changes, or device therapy. In addition, the change in peak VO 2 may have prognostic implications for individuals with chronic HF. 8
Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was a multicenter clinical trial designed to study the effects of exercise training on mortality and morbidity in 2331 patients with New York Heart Association class II to class IV chronic systolic HF receiving guidelines-based optimal medical therapy. Eighty-two clinical sites participated in this trial, with 67 from the United States, 9 from Canada, and 6 from France. Patients enrolled in HF-ACTION were followed for a maximum of 4 years after baseline testing, with a median follow-up time of 30.1 months. After the first 3 months, the exercise training group demonstrated a modest increase in peak VO 2 in comparison with the usual care group (0.6 [Q1 to Q3=−0.7 to 2.3] versus 0.2 [Q1 to Q3=−1.2 to 1.4] mL‧kg −1 ‧min −1 , P<0.001). 12 HF-ACTION was designed to be sufficiently powered to assess the impact of a change in peak VO 2 on clinical outcomes. Thus, the specific aims of the current analysis were 2-fold: (1) to determine whether an increase in peak VO 2 was associated with a lower risk of the composite primary end point of time to all-cause mortality or all-cause hospitalization; and (2) to determine whether an increase in peak VO 2 was associated with a lower risk of 3 secondary end points, including time to cardiovascular mortality or cardiovascular hospitalization, cardiovascular mortality or HF hospitalization, and all-cause mortality.
Methods
The eligibility characteristics for subject enrollment and methodology for the exercise testing and training protocols for HF-ACTION have been presented previously. 13 Subjects had left ventricular ejection fractions (LVEF) ≤35% by echocardiography and New York Heart Association class II to class IV HF symptoms despite optimal HF therapy for at least 6 weeks. Cardiopulmonary exercise (CPX) testing was performed prerandomization and at ≈3 months after randomization using an extended, modified Naughton treadmill protocol or ramp (10 W/min) stationary cycle protocol. There were 1620 subjects who underwent CPX testing at the prerandomization and 3-month time points and who did not experience the primary end point before the 3-month CPX test. The data from these 1620 subjects, (combined exercise training and usual care groups of HF-ACTION) are presented in this article. Figure 1 shows the flow of these 1620 subjects through this trial. Of these 1620 subjects, 92% were tested on a treadmill, whereas 8% used a cycle ergometer. During CPX testing, subjects were encouraged to achieve a rating of perceived exertion of ≥17 (hard to very hard) on the 6 to 20 Borg scale and a respiratory exchange ratio of >1.10. Gas exchange results were forwarded to the CPX core laboratory, where 2 independent experts who were blinded to the subjects' treatment assignments determined peak VO 2 . Peak VO 2 was operationally defined as the highest VO 2 for a given 15-or 20-second interval within the last 90 seconds of exercise or the first 30 seconds of recovery. 13 After the initial CPX test, subjects were randomized to either usual care alone or usual care and exercise training. Due to the nature of the intervention, blinding for subjects and site investigators was not possible. However, deaths and cardiovascular hospitalizations for each patient were adjudicated by a clinical endpoint committee blinded to treatment assignment. Once a patient had an adjudicated HF hospitalization, no further hospitalizations for that patient were reviewed. 12
Statistical Analysis
Subject characteristics were summarized by percentages for categorical variables and median with interquartile range for continuous variables. Model development for the primary end point of all-cause mortality or all-cause hospitalization and secondary end points of cardiovascular mortality or cardiovascular hospitalization, cardiovascular mortality or HF hospitalization and for the all-cause mortality end point proceeded similarly. In each case, the procedure began with imputation of missing values of potential predictors identified in the main outcomes article 12 as well as additional predictors related to quality-of-life questionnaire responses and oxygen pulse. The imputation algorithm used the values of the all-cause mortality or all-cause hospitalization end point to impute the values of missing potential predictors in the imputation process. Although 78% of the potential predictors had <1% missing data, an additional 18% had 1% to 5% missing data. Only 2 potential predictors, VO 2 at ventilatory threshold (17%) and hemoglobin (24%), had >15% missing data.
The univariate relationship of each continuous variable with outcome was checked for linearity of the log hazard ratio, and piecewise linear splines were used as transformations when appropriate. 14 A bootstrapped backward selection algorithm of a Cox proportional hazards model was used for model selection, and the C-index was used to choose the final model. 15 A similar process was followed in the modeling of the change in peak VO 2 , using linear regression rather than Cox proportional hazard and the adjusted model R square statistic rather than the C-index. All Cox analyses used the date of the subject's 3-month CPX test for time zero, which provided the basis for days to end point or censoring. On the basis of prior studies showing that a 6% change in peak VO 2 is clinically meaningful in HF patients, 7 the effect of a 6% increase in peak VO 2 on primary and secondary outcomes was assessed in separate multivariate models for each clinical outcome. In addition, tertiles of change in peak VO 2 were calculated in the overall sample. Trend tests across the tertiles of percent change in peak VO 2 for each clinical outcome were done using models in which the tertiles of peak VO 2 change were fit as a continuous variable. Survival curves adjusted for significant covariates were constructed by calculating the average survival across all of the patients. 16 A 2-tailed P<0.05 was required to reject the null hypothesis. Table 1 presents relevant subject characteristics at baseline. Median age for the group was 59 years, and 28% of patients were women. Baseline median LVEF was 25% and HF was of an ischemic pathogenesis in 52% of the population studied. Ninety-five percent of subjects were taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Ninety-five percent of subjects were also on β-blocker therapy. Sixty-seven percent of the subjects were classified as New York Heart Association class II and 32% as New York Heart Association class III. The median baseline peak VO 2 was 15.0 mL‧kg −1 ‧min −1 , and median baseline VO 2 at ventilatory threshold was 10.8 mL‧kg −1 ‧min −1 . Table 2 presents the relation between the change in peak VO 2 at 3 months and the primary and secondary end points after accounting for significant predictors. The significant predictors for each clinical outcome are also presented in Table  2 . An increase in peak VO 2 from baseline to 3 months was related to a significantly lower risk for the primary outcome of time to all-cause mortality or all-cause hospitalization (hazard ratio=0.95; CI=0.93-0.98; P<0.001). For each 6% increase in peak VO 2 , there was a 5% lower risk for this end point. A 6% increase in peak VO 2 from baseline to 3 months was related to a 4% lower risk of the secondary end point of cardiovascular mortality or cardiovascular hospitalization (hazard ratio=0.96; CI=0.94-0.99; P<0.001). A 6% increase in peak VO 2 from baseline to 3 months was related to an 8% lower risk of the secondary end point of cardiovascular mortality or HF (11) South USA n/N (%) 567/1620 (35) Canada n/N (%) 150/1620 (9) France n/N (%) 37/1620 (2) NYHA class at randomization (26) Prior valve surgery n/N (%) 77/1620 (5) Prior PCI n/N (%) 367/1620 (23) History of COPD n/N (%) 175/1604 (11) History of PVD n/N (%) 96/1611 (6) History of depression n/N (%) 322/1620 (20) History of atrial fibrillation or atrial flutter n/N (%) 338/1620 (21) Renal dysfunction n/N (%) 18/1447 (1) Medications and devices at baseline On a biventricular pacemaker at baseline n/N (%) 292/1620 (18) On pacemaker at baseline n/N (%) 284/1620 ( ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CPX, cardiopulmonary exercise test; IVCD, intraventricular conduction defect; LBBB, left bundle branch block; NYHA, New York Heart Association Class; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RBBB, right bundle branch block; VO 2 , oxygen uptake; VE, ventilation; VCO 2 , volume of carbon dioxide produced; RER, respiratory exchange ratio; and HR, heart rate.
Results
*Subset of patients from HF-ACTION cohort who were not missing baseline or 3-month peak VO 2 , and free of primary end point events through the 3-month measurement.
(continued) hospitalization (hazard ratio=0.92; CI=0.88-0.96; P<0.001). A 6% increase in peak VO 2 from baseline to 3 months was related to a 7% lower risk of the secondary end point of allcause mortality (hazard ratio=0.93; CI=0.90-0.97; P<0.001). Similarly, significant although smaller HR reductions were seen for a 4% increase in peak VO 2 , the mean change in the training arm (data not shown). Table 3 presents trend tests for each clinical outcome. With the exception of cardiovascular mortality or HF hospitalization, a significant trend for better outcomes was observed from lowest to highest tertiles of peak VO 2 change. Figure 2 presents adjusted survival curves for the 1620 subjects for each of the clinical end points stratified by change in peak VO 2 . Only the primary end point of time to all-cause mortality or all-cause hospitalization demonstrated a significant difference in event rates. Specifically, individuals whose peak VO 2 decreased by <6% experienced a 9% lower event rate at 3 years compared with those individuals whose peak VO 2 changed less than this amount. Figure 3 presents an algorithm for using the change in peak VO 2 as assessed in the current study with repeat CPX testing and evaluating HF prognosis for the clinician. This algorithm allows the clinician some opportunity to consider alternative therapies based on the measured change in peak VO 2 .
Discussion
HF-ACTION is the largest study to address whether a change in peak VO 2 is related to mortality and morbidity clinical end points for individuals with chronic HF. The results confirm the hypotheses that an increase in peak VO 2 was significantly related to a lower event rate for the primary and each of the 3 secondary clinical end points. Specifically, for each 6% increase in peak VO 2 over 3 months there was a 5% lower risk for the primary outcome of all-cause mortality and all-cause hospitalization, a 4% lower risk for the secondary end point of time to cardiovascular mortality or cardiovascular hospitalizations, an 8% lower risk for cardiovascular mortality or HF hospitalizations, and a 7% decreased risk for all-cause mortality after accounting for other significant predictors. A 6% increase in peak VO 2 was achieved by 33% of the patients randomized to usual care and 44% of the patients randomized to exercise training.
Other studies 7-11 that have evaluated the change in peak VO 2 and related the change to clinical outcomes in HF patients have had relatively small sample sizes, and their findings have not been consistent. Corrà et al 7 studied 231 stable chronic HF patients, of which 200 were men, with a peak VO 2 of 14.3±8 mL·kg −1 ·min −1 and LVEF of 24%±8%, who underwent 2 CPX tests separated by 258±42 days. They observed that the change in peak VO 2 had significant prognostic ability. Survival analysis indicated that 51% of subjects having a decrease in peak VO 2 did not survive for the followup period of 1167±562 days compared with 14% of subjects with an increase in peak VO 2 . 3 Stevenson et al 10 evaluated 83 HF patients who underwent CPX testing between 3 and 12 months after their initial evaluation. Patients who demonstrated an increase in peak VO 2 of >2 mL·kg −1 ·min −1 or a peak VO 2 >12 mL·kg −1 ·min −1 showed a better survival rate. Florea et al 8 studied 62 chronic HF patients, of which 58 were men, with a mean peak VO 2 of 18.2±5.9 mL·kg −1 ·min −1 and a mean LVEF of 38.9%±15.8% and found that the change in peak VO 2 monitored over 24 months, predicted nontransplant survival. In contrast, Gullestad et al 9 reported that the change in peak VO 2 assessed by 2 separate CPX tests performed 7.8 months apart did not add any prognostic information in 283 HF patients with a mean peak VO 2 of 16.7±0.3 mL·kg −1 ·min −1 being evaluated for heart transplantation. In 155 stable chronic HF patients studied before and after 20 supervised exercise training sessions, Tabet et al 11 found that the change in peak VO 2 and B-type natriuretic peptide level were the only significant independent predictors of clinical outcomes. Similar to our own findings, the investigators found that the lack of improvement in exercise capacity had prognostic value for adverse clinical events. Finally, in 417 coronary patients without evident HF, Vanhees et al 17 observed that every 1% increase in peak VO 2 after a 3-month training program was associated with a 2% lower risk of cardiovascular death.
Several possible factors might contribute to a change in peak VO 2 over time, including random variation, a familiarization effect with repeated testing, the natural history of the disease, a change in physical activity patterns, a change in drug Covariates in the final model for each clinical end point with treatment arm forced into all models. All-cause mortality or all-cause hospitalization: change in peak VO 2 at 3 months; baseline peak VO 2 ; KCC total symptom score; ventricular conduction on CPX; LVEF; mitral regurgitation grade; on nitrate; BUN; sex; region; β-blocker dose.
Cardiovascular mortality or cardiovascular hospitalization: change in peak VO 2 at 3 months; ventricular conduction on CPX; LVEF; mitral regurgitation grade; on nitrate; BUN; sex; region; β-blocker dose.
Cardiovascular mortality or heart failure hospitalization; change in peak VO 2 at 3 months; ventricular conduction on CPX; LVEF; mitral regurgitation grade; BUN; loop diuretic dose; sex; peak RER on CPX; region; β-blocker dose.
Mortality: change in peak VO 2 at 3 months; ventricular conduction on CPX; LVEF; mitral regurgitation grade; BUN; loop diuretic dose; sex; marital status; baseline peak VO 2 ; region and β-blocker dose. regimen, or cardiac resynchronization (biventricular) pacing therapy. [3] [4] [5] [6] In this study, exercise training is a potential reason for the observed changes in peak VO 2 because it represents the intervention under investigation. Despite exercise group assignment not appearing as an independent covariate in predicting clinical outcomes, a significantly greater increase in mean peak VO 2 (0.6 mL·kg −1 ·min −1 for exercise training and usual care in comparison with an increase of 0.2 mL·kg −1 ·min −1 for usual care alone, respectively) was observed after 3 months. 12 The majority of single-site randomized controlled trials have observed a significant increase in peak VO 2 with exercise training for individuals with chronic HF, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] although not all studies have observed significant changes. [28] [29] [30] [31] [32] Singlesite studies however, are typically not designed to address the relation between the change in peak VO 2 and clinical outcomes, nor are they powered to do so. 27 The mechanism for an increase in peak VO 2 impacting clinical outcomes related to mortality and morbidity likely involves a number of factors. The determinants of peak VO 2 include central (heart rate, stroke volume, cardiac output) and peripheral (muscle oxygen extraction) components. Each of these factors tends to respond favorably (positively) to exercise training for most individuals with chronic HF. Exercise training induces significant increases in maximal heart rate 25 ; stroke volume, 23 cardiac output, 33, 34 arterial-venous O 2 difference, 35 skeletal muscle blood flow, likely related to reversal of endothelial dysfunction 22, 24 ; skeletal muscle oxidative function 19, 21, 29, 34, 36 ; attenuation of sympathetic activation 18, 28, 33, 37 ; and increases in chronotropic responsiveness in such patients. 18, 26 Exercise training also attenuates the production of proinflammatory cytokines and natriuretic peptides. 38, 39 In addition to the responses already noted, increased blood vessel formation, a higher threshold for arrhythmias and sudden death, and healthier lifestyle decisions that accompany a change in fitness level may also help explain the positive relation between an increase in peak VO 2 and clinical outcomes. 20 This investigation had the following limitations. The HF patients enrolled in this study were younger and with fewer comorbid conditions compared with the general population with HF, and this study only included patients with reduced Figure 2 . Adjusted survival curves for the 1620 subjects who completed prerandomization and 3-month cardiopulmonary exercise (CPX) tests categorized by direction of changes in peak oxygen uptake (VO 2 ) over time for the primary outcome of all-cause mortality or allcause hospitalization and 3 secondary end points, including time to cardiovascular mortality or cardiovascular hospitalization, cardiovascular mortality or heart failure (HF) hospitalization, and all-cause mortality.
LVEF (systolic HF). The exercise intervention was not blinded to either patient or site investigator; however, all CPX tests were reviewed by experts from a core laboratory who were blinded to treatment assignment. Despite extensive efforts, adherence to exercise training was less than optimal, with about 40% of patients at 3 months and about 35% of patients in year 2 training at or above the target number of minutes per week. The improvements in peak VO 2 with training were less than in many other studies and limit the ability to determine whether greater improvements in peak VO 2 would have resulted in larger differences in clinical outcomes. Although the change in peak VO 2 observed in the current study is less than the within-subject absolute variation of 1.3 mL·kg −1 ·min −1 measured with repeated CPX testing in HF patients observed by Bensimhon et al, 40 chance variation in peak VO 2 would not likely be associated with differences in clinical outcomes as observed here. Because of the fact that ≈30% of the randomized subjects were excluded from our analyses because they either did not have a baseline or 3-month CPX test or experienced a primary outcome before the 3-month test, these findings should be interpreted with caution as they involve a more select group of patients than the overall HF-ACTION trial cohort. Unmeasured confounding variables may account for some or all of these findings. Imputation of missing data, particularly variables with >15% missing may have added some bias to the selection of the predictor variables for the final model.
Notwithstanding these limitations, several strengths of the current analysis are noteworthy. The large sample, which is more than twice that of prior similar studies 7-11 combined, the inclusion of large numbers of women and minorities, and the high use of evidence-based background therapy make our findings relevant to clinical practice. The protocol-based CPX testing 3 months after baseline assessment, with analysis by blinded core laboratory personnel provided further quality assurance.
In summary, the results of this secondary analysis of the largest randomized trial of exercise training in HF patients indicate that a modest increase in peak VO 2 over 3 months is associated with a lower composite rate of all-cause mortality and all-cause hospitalization, even in the setting of optimal medical and device therapy for chronic systolic HF. Because exercise training and other interventions can be effective therapy in improving aerobic exercise tolerance, a key limiting factor in patients with HF, these findings suggest that monitoring the change in peak VO 2 over time may be useful in this setting.
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